{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T02:51:12Z","timestamp":1785898272225,"version":"3.56.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:00:00Z","timestamp":1747353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biol Rep"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11033-025-10527-x","type":"journal-article","created":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T13:49:07Z","timestamp":1747403347000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["C-type lectin-like molecule-1 as a diagnostic, prognostic, and therapeutic marker in leukemia"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1045-7613","authenticated-orcid":false,"given":"Hamed","family":"Soleimani Samarkhazan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5998-1722","authenticated-orcid":false,"given":"Sara","family":"Zehtabcheh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Peyvasteh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4884-5218","authenticated-orcid":false,"given":"Mohammad Hossein","family":"Mohammadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,16]]},"reference":[{"issue":"7","key":"10527_CR1","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/bcj.2016.50","volume":"6","author":"I De Kouchkovsky","year":"2016","unstructured":"De Kouchkovsky I, Abdul-Hay M (2016) Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J 6(7):e441","journal-title":"Blood Cancer J"},{"key":"10527_CR2","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2024.5700","author":"J Li","year":"2024","unstructured":"Li J et al (2024) Advancements in leukemia management: bridging diagnosis, prognosis and nanotechnology (Review). Int J Oncol. https:\/\/doi.org\/10.3892\/ijo.2024.5700","journal-title":"Int J Oncol"},{"issue":"1","key":"10527_CR3","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s13045-021-01062-w","volume":"14","author":"H Liu","year":"2021","unstructured":"Liu H (2021) Emerging agents and regimens for AML. J Hematol Oncol 14(1):49","journal-title":"J Hematol Oncol"},{"key":"10527_CR4","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.blre.2018.10.003","volume":"34","author":"LM Morsink","year":"2019","unstructured":"Morsink LM, Walter RB, Ossenkoppele GJ (2019) Prognostic and therapeutic role of CLEC12A in acute myeloid leukemia. Blood Rev 34:26\u201333","journal-title":"Blood Rev"},{"key":"10527_CR5","doi-asserted-by":"crossref","first-page":"6643948","DOI":"10.1155\/2021\/6643948","volume":"2021","author":"J Wang","year":"2021","unstructured":"Wang J et al (2021) C-type lectin-like molecule-1 as a biomarker for diagnosis and prognosis in acute myeloid leukemia: a preliminary study. Biomed Res Int 2021:6643948","journal-title":"Biomed Res Int"},{"key":"10527_CR6","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3389\/fimmu.2020.00251","volume":"11","author":"M Drouin","year":"2020","unstructured":"Drouin M, Saenz J, Chiffoleau E (2020) C-type lectin-like receptors: head or tail in cell death immunity. Front Immunol 11:251","journal-title":"Front Immunol"},{"key":"10527_CR7","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1016\/j.csbj.2022.10.019","volume":"20","author":"S Fischer","year":"2022","unstructured":"Fischer S et al (2022) From structure to function\u2014ligand recognition by myeloid C-type lectin receptors. Comput Struct Biotechnol J 20:5790\u20135812","journal-title":"Comput Struct Biotechnol J"},{"issue":"4","key":"10527_CR8","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1111\/jcmm.13519","volume":"22","author":"M Bill","year":"2018","unstructured":"Bill M et al (2018) Mapping the CLEC12A expression on myeloid progenitors in normal bone marrow; implications for understanding CLEC12A-related cancer stem cell biology. J Cell Mol Med 22(4):2311\u20132318","journal-title":"J Cell Mol Med"},{"issue":"1","key":"10527_CR9","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s40364-025-00738-6","volume":"13","author":"H Soleimani Samarkhazan","year":"2025","unstructured":"Soleimani Samarkhazan H et al (2025) Unveiling the potential of CLL-1: a promising target for AML therapy. Biomarker Res 13(1):28","journal-title":"Biomarker Res"},{"issue":"1","key":"10527_CR10","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s11033-024-10200-9","volume":"52","author":"L Rajabi","year":"2025","unstructured":"Rajabi L et al (2025) Aqueous and ethanolic extracts of Moringa oleifera leaves induce selective cytotoxicity in Raji and Jurkat cell lines by activating the P21 pathway independent of P53. Mol Biol Rep 52(1):102","journal-title":"Mol Biol Rep"},{"issue":"36","key":"10527_CR11","doi-asserted-by":"crossref","first-page":"57811","DOI":"10.18632\/oncotarget.11063","volume":"7","author":"NH Darwish","year":"2016","unstructured":"Darwish NH et al (2016) Acute myeloid leukemia stem cell markers in prognosis and targeted therapy: potential impact of BMI-1, TIM-3 and CLL-1. Oncotarget 7(36):57811\u201357820","journal-title":"Oncotarget"},{"issue":"1","key":"10527_CR12","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/cyto.b.20614","volume":"82","author":"H Larsen","year":"2012","unstructured":"Larsen H et al (2012) Expression of the hMICL in acute myeloid leukemia-a highly reliable disease marker at diagnosis and during follow-up. Cytometry B Clin Cytom 82(1):3\u20138","journal-title":"Cytometry B Clin Cytom"},{"issue":"3","key":"10527_CR13","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/cyto.b.21540","volume":"94","author":"M Toft-Petersen","year":"2018","unstructured":"Toft-Petersen M et al (2018) The CLEC12A receptor marks human basophils: potential implications for minimal residual disease detection in acute myeloid leukemia. Cytometry B Clin Cytom 94(3):520\u2013526","journal-title":"Cytometry B Clin Cytom"},{"issue":"1","key":"10527_CR14","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-022-01308-1","volume":"15","author":"X Jin","year":"2022","unstructured":"Jin X et al (2022) First-in-human phase I study of CLL-1 CAR-T cells in adults with relapsed\/refractory acute myeloid leukemia. J Hematol Oncol 15(1):88","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10527_CR15","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3324\/haematol.2009.009811","volume":"95","author":"X Zhao","year":"2010","unstructured":"Zhao X et al (2010) Targeting C-type lectin-like molecule-1 for antibody-mediated immunotherapy in acute myeloid leukemia. Haematologica 95(1):71\u201378","journal-title":"Haematologica"},{"key":"10527_CR16","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1182\/blood-2018-99-110579","volume":"132","author":"F Liu","year":"2018","unstructured":"Liu F et al (2018) First-in-human CLL1-CD33 compound CAR T cell therapy induces complete remission in patients with refractory acute myeloid leukemia: update on phase 1 clinical trial. Blood 132:901","journal-title":"Blood"},{"issue":"5","key":"10527_CR17","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/bjh.15711","volume":"184","author":"M Bill","year":"2019","unstructured":"Bill M et al (2019) Revisiting CLEC12A as leukaemic stem cell marker in AML: highlighting the necessity of precision diagnostics in patients eligible for targeted therapy. Br J Haematol 184(5):769\u2013781","journal-title":"Br J Haematol"},{"issue":"3","key":"10527_CR18","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1111\/ejh.13672","volume":"107","author":"LL Ngai","year":"2021","unstructured":"Ngai LL et al (2021) Bimodal expression of potential drug target CLL-1 (CLEC12A) on CD34+ blasts of AML patients. Eur J Haematol 107(3):343\u2013353","journal-title":"Eur J Haematol"},{"issue":"1","key":"10527_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/ajcp\/aqac070","volume":"158","author":"OK Weinberg","year":"2022","unstructured":"Weinberg OK, Arber DA (2022) How I diagnose acute leukemia of ambiguous lineage. Am J Clin Pathol 158(1):27\u201334","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"10527_CR20","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1182\/blood.2020006921","volume":"137","author":"S Willier","year":"2021","unstructured":"Willier S et al (2021) CLEC12A and CD33 coexpression as a preferential target for pediatric AML combinatorial immunotherapy. Blood 137(8):1037\u20131049","journal-title":"Blood"},{"issue":"5","key":"10527_CR21","doi-asserted-by":"crossref","first-page":"e0197823","DOI":"10.1371\/journal.pone.0197823","volume":"13","author":"BN Ostendorf","year":"2018","unstructured":"Ostendorf BN et al (2018) Phenotypic characterization of aberrant stem and progenitor cell populations in myelodysplastic syndromes. PLoS One 13(5):e0197823","journal-title":"PLoS One"},{"issue":"3","key":"10527_CR22","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/bjh.14270","volume":"175","author":"M Toft-Petersen","year":"2016","unstructured":"Toft-Petersen M et al (2016) Unravelling the relevance of CLEC12A as a cancer stem cell marker in myelodysplastic syndrome. Br J Haematol 175(3):393\u2013401","journal-title":"Br J Haematol"},{"issue":"3","key":"10527_CR23","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41375-023-01811-5","volume":"37","author":"MF van Spronsen","year":"2023","unstructured":"van Spronsen MF et al (2023) Immunophenotypic aberrant hematopoietic stem cells in myelodysplastic syndromes: a biomarker for leukemic progression. Leukemia 37(3):680\u2013690","journal-title":"Leukemia"},{"issue":"8","key":"10527_CR24","doi-asserted-by":"crossref","first-page":"e352","DOI":"10.3324\/haematol.2018.214353","volume":"104","author":"D Schinnerl","year":"2019","unstructured":"Schinnerl D et al (2019) CD371 cell surface expression: a unique feature of DUX4-rearranged acute lymphoblastic leukemia. Haematologica 104(8):e352\u2013e355","journal-title":"Haematologica"},{"issue":"10","key":"10527_CR25","doi-asserted-by":"crossref","first-page":"300060523120384","DOI":"10.1177\/03000605231203842","volume":"51","author":"H Shakah","year":"2023","unstructured":"Shakah H et al (2023) Flow cytometric signature of CD371-positive B-cell acute lymphoblastic leukemia. J Int Med Res 51(10):3000605231203842","journal-title":"J Int Med Res"},{"issue":"1","key":"10527_CR26","doi-asserted-by":"crossref","first-page":"e7","DOI":"10.1111\/bjh.17122","volume":"192","author":"H Matsuo","year":"2021","unstructured":"Matsuo H et al (2021) Blast cells in acute megakaryoblastic leukaemia with down syndrome are characterized by low CLEC12A expression. Br J Haematol 192(1):e7\u2013e11","journal-title":"Br J Haematol"},{"issue":"1","key":"10527_CR27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10238-025-01588-0","volume":"25","author":"A Raoufi","year":"2025","unstructured":"Raoufi A et al (2025) Macrophages in graft-versus-host disease (GVHD): dual roles as therapeutic tools and targets. Clin Exp Med 25(1):73","journal-title":"Clin Exp Med"},{"issue":"9","key":"10527_CR28","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1080\/10428194.2022.2064986","volume":"63","author":"Q Li","year":"2022","unstructured":"Li Q et al (2022) CLEC12A plays an important role in immunomodulatory function and prognostic significance of patients with acute myeloid leukemia. Leuk Lymphoma 63(9):2136\u20132148","journal-title":"Leuk Lymphoma"},{"key":"10527_CR29","doi-asserted-by":"crossref","first-page":"1252258","DOI":"10.3389\/fimmu.2024.1252258","volume":"15","author":"N \u00c1lvarez","year":"2024","unstructured":"\u00c1lvarez N et al (2024) Detection of minimal residual disease in acute myeloid leukemia: evaluating utility and challenges. Front Immunol 15:1252258","journal-title":"Front Immunol"},{"issue":"13","key":"10527_CR30","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.3390\/cancers16132359","volume":"16","author":"F Mosna","year":"2024","unstructured":"Mosna F (2024) The immunotherapy of acute myeloid leukemia: a clinical point of view. Cancers (Basel) 16(13):2359","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10527_CR31","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/14712598.2019.1623200","volume":"19","author":"PF van Loo","year":"2019","unstructured":"van Loo PF et al (2019) MCLA-117, a CLEC12AxCD3 bispecific antibody targeting a leukaemic stem cell antigen, induces T cell-mediated AML blast lysis. Expert Opin Biol Ther 19(7):721\u2013733","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"10527_CR32","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1038\/s41375-020-01065-5","volume":"35","author":"US Arvindam","year":"2021","unstructured":"Arvindam US et al (2021) A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells. Leukemia 35(6):1586\u20131596","journal-title":"Leukemia"},{"issue":"14","key":"10527_CR33","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1158\/1078-0432.CCR-15-2710","volume":"22","author":"DA Vallera","year":"2016","unstructured":"Vallera DA et al (2016) IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin Cancer Res 22(14):3440\u20133450","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10527_CR34","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1038\/s41375-021-01253-x","volume":"35","author":"N Daver","year":"2021","unstructured":"Daver N et al (2021) T-cell-based immunotherapy of acute myeloid leukemia: current concepts and future developments. Leukemia 35(7):1843\u20131863","journal-title":"Leukemia"},{"issue":"3","key":"10527_CR35","first-page":"28","volume":"11","author":"A Noroozi Aghide","year":"2016","unstructured":"Noroozi Aghide A, Soleimani Samarkhazan H, Ahmadnezhad M (2016) Effect of harmine alkaloid on the expression of P16 and DAPK in HL60 leukemia cell line. Paramed Sci Military Health 11(3):28\u201333","journal-title":"Paramed Sci Military Health"},{"issue":"1","key":"10527_CR36","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/s41375-018-0180-3","volume":"33","author":"S Haubner","year":"2019","unstructured":"Haubner S et al (2019) Coexpression profile of leukemic stem cell markers for combinatorial targeted therapy in AML. Leukemia 33(1):64\u201374","journal-title":"Leukemia"},{"issue":"11","key":"10527_CR37","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","volume":"18","author":"E Laborda","year":"2017","unstructured":"Laborda E et al (2017) Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci 18(11):2259","journal-title":"Int J Mol Sci"},{"issue":"14","key":"10527_CR38","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1182\/bloodadvances.2018020107","volume":"2","author":"YP Jiang","year":"2018","unstructured":"Jiang YP et al (2018) CLT030, a leukemic stem cell-targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia. Blood Adv 2(14):1738\u20131749","journal-title":"Blood Adv"},{"issue":"4","key":"10527_CR39","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1158\/1078-0432.CCR-18-0333","volume":"25","author":"B Zheng","year":"2019","unstructured":"Zheng B et al (2019) An Anti-CLL-1 antibody-drug conjugate for the treatment of acute myeloid leukemia. Clin Cancer Res 25(4):1358\u20131368","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10527_CR40","doi-asserted-by":"crossref","first-page":"E175","DOI":"10.1002\/ajh.26136","volume":"96","author":"N Daver","year":"2021","unstructured":"Daver N et al (2021) A Phase I dose-escalation study of DCLL9718S, an antibody-drug conjugate targeting C-type lectin-like molecule-1 (CLL-1) in patients with acute myeloid leukemia. Am J Hematol 96(5):E175-e179","journal-title":"Am J Hematol"},{"issue":"1","key":"10527_CR41","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13045-019-0726-5","volume":"12","author":"H Ma","year":"2019","unstructured":"Ma H et al (2019) Targeting CLL-1 for acute myeloid leukemia therapy. J Hematol Oncol 12(1):41","journal-title":"J Hematol Oncol"},{"issue":"1","key":"10527_CR42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13045-017-0553-5","volume":"11","author":"J Wang","year":"2018","unstructured":"Wang J et al (2018) CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia. J Hematol Oncol 11(1):7","journal-title":"J Hematol Oncol"},{"issue":"11","key":"10527_CR43","doi-asserted-by":"crossref","first-page":"2596","DOI":"10.1038\/s41375-022-01703-0","volume":"36","author":"H Zhang","year":"2022","unstructured":"Zhang H et al (2022) Characteristics of anti-CLL1 based CAR-T therapy for children with relapsed or refractory acute myeloid leukemia: the multi-center efficacy and safety interim analysis. Leukemia 36(11):2596\u20132604","journal-title":"Leukemia"},{"issue":"11","key":"10527_CR44","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.3390\/ijms18112259","volume":"18","author":"E Laborda","year":"2017","unstructured":"Laborda E et al (2017) Development of a chimeric antigen receptor targeting C-type lectin-like molecule-1 for human acute myeloid leukemia. Int J Mol Sci 18(11):2259","journal-title":"Int J Mol Sci"},{"issue":"37","key":"10527_CR45","doi-asserted-by":"crossref","first-page":"9841","DOI":"10.1002\/anie.201405353","volume":"53","author":"H Lu","year":"2014","unstructured":"Lu H et al (2014) Targeting human C-type lectin-like molecule-1 (CLL1) with a bispecific antibody for immunotherapy of acute myeloid leukemia. Angew Chem Int Ed Engl 53(37):9841\u20139845","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1","key":"10527_CR46","first-page":"1","volume":"3","author":"M Farrokhi","year":"2023","unstructured":"Farrokhi M et al (2023) Role of precision medicine and personalized medicine in the treatment of diseases. Kindle 3(1):1\u2013164","journal-title":"Kindle"}],"container-title":["Molecular Biology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11033-025-10527-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11033-025-10527-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T16:30:27Z","timestamp":1766853027000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11033-025-10527-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,16]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10527"],"URL":"https:\/\/doi.org\/10.1007\/s11033-025-10527-x","relation":{},"ISSN":["0301-4851","1573-4978"],"issn-type":[{"value":"0301-4851","type":"print"},{"value":"1573-4978","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,16]]},"assertion":[{"value":"7 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"464"}}